Influencing factors for the homing ability of mesenchymal stem cells in end-stage liver disease and optimization measures

Yuxin LIU; Liaoyun ZHANG

doi:10.12449/JCH250326

Volume 41 Issue 3

Mar. 2025

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2025 > 41(3): 561-567

PDF( 761 KB)

Influencing factors for the homing ability of mesenchymal stem cells in end-stage liver disease and optimization measures

DOI: 10.12449/JCH250326

Yuxin LIU,
Liaoyun ZHANG^{,
,}

Department of Infectious Diseases，The First Hospital of Shanxi Medical University，Taiyuan 030001，China

Research funding:

Key R & D Projects of Shanxi Province (201903D421056)

More Information

Corresponding author: ZHANG Liaoyun， zlysgzy@163.com （ORCID： 0000-0002-7666-7368）
Received Date: 2024-06-16
Accepted Date: 2024-08-22
Published Date: 2025-03-25

Abstract

Abstract

Mesenchymal stem cells （MSCs） have emerged as a promising cellular therapy for end-stage liver disease （ESLD） due to their robust self-regenerative， paracrine， and immunomodulatory characteristics， providing new directions for the treatment of advanced liver disease. However， the clinical application of MSCs is significantly limited by the fact that only a small number of MSCs can reach the liver due to massive apoptosis or necrosis during the homing process caused by the influence of the complex microenvironment （inflammation， oxidative stress， and hypoxia） of the injured liver and the fact that a substantial proportion of MSCs become trapped in the pulmonary capillaries following intravenous administration with a lack of sufficient homing receptors or adhesion molecules. Various strategies have been developed to optimize the proliferation， migration， and homing abilities of MSCs， including preconditioning， gene modification， and nanoencapsulation technology. This article elaborates on the influencing factors for the homing ability of MSCs， the strategies to optimize their homing in ESLD， and the mechanism of the homing of MSCs， in order to improve cell transplantation efficiency， promote liver repair and regeneration， and pave the way for the application of MSCs in the treatment of ESLD.
- End Stage Liver Disease,
- Mesenchymal Stem Cells,
- Homing

FullText(HTML)

References(40)

References

[1]	YU SX, YU SH, LIU HY, et al. Enhancing mesenchymal stem cell survival and homing capability to improve cell engraftment efficacy for liver diseases[J]. Stem Cell Res Ther, 2023, 14( 1): 235. DOI: 10.1186/s13287-023-03476-4.
[2]	MEI RY, WAN Z, YANG C, et al. Advances and clinical challenges of mesenchymal stem cell therapy[J]. Front Immunol, 2024, 15: 1421854. DOI: 10.3389/fimmu.2024.1421854.
[3]	FAGOONEE S, SHUKLA SP, DHASMANA A, et al. Routes of stem cell administration[J]. Adv Exp Med Biol, 2022. DOI: 10.1007/5584_2022_710.[ Online ahead of print]
[4]	GHUFRAN H, AZAM M, MEHMOOD A, et al. Adipose tissue and umbilical cord tissue: Potential sources of mesenchymal stem cells for liver fibrosis treatment[J]. J Clin Exp Hepatol, 2024, 14( 4): 101364. DOI: 10.1016/j.jceh.2024.101364.
[5]	HASS R, KASPER C, BÖHM S, et al. Different populations and sources of human mesenchymal stem cells(MSC): A comparison of adult and neonatal tissue-derived MSC[J]. Cell Commun Signal, 2011, 9: 12. DOI: 10.1186/1478-811X-9-12.
[6]	JERVIS M, HUAMAN O, CAHUASCANCO B, et al. Comparative analysis of in vitro proliferative, migratory and pro-angiogenic potentials of bovine fetal mesenchymal stem cells derived from bone marrow and adipose tissue[J]. Vet Res Commun, 2019, 43( 3): 165- 178. DOI: 10.1007/s11259-019-09757-9.
[7]	SHI LH, CHEN LL, GAO XZ, et al. Comparison of different sources of mesenchymal stem cells: Focus on inflammatory bowel disease[J]. Inflammopharmacology, 2024, 32( 3): 1721- 1742. DOI: 10.1007/s10787-024-01468-1.
[8]	SINEH SEPEHR K, RAZAVI A, HASSAN ZM, et al. Comparative immunomodulatory properties of mesenchymal stem cells derived from human breast tumor and normal breast adipose tissue[J]. Cancer Immunol Immunother, 2020, 69( 9): 1841- 1854. DOI: 10.1007/s00262-020-02567-y.
[9]	KABAT M, BOBKOV I, KUMAR S, et al. Trends in mesenchymal stem cell clinical trials 2004-2018: Is efficacy optimal in a narrow dose range?[J]. Stem Cells Transl Med, 2020, 9( 1): 17- 27. DOI: 10.1002/sctm.19-0202.
[10]	LI M, ZHANG JG, FANG JM, et al. Pre-administration of human umbilical cord mesenchymal stem cells has better therapeutic efficacy in rats with D-galactosamine-induced acute liver failure[J]. Int Immunopharmacol, 2024, 130: 111672. DOI: 10.1016/j.intimp.2024.111672.
[11]	YANG H, CHEN JX, LI J. Isolation, culture, and delivery considerations for the use of mesenchymal stem cells in potential therapies for acute liver failure[J]. Front Immunol, 2023, 14: 1243220. DOI: 10.3389/fimmu.2023.1243220.
[12]	YUAN MQ, HU X, YAO LC, et al. Mesenchymal stem cell homing to improve therapeutic efficacy in liver disease[J]. Stem Cell Res Ther, 2022, 13( 1): 179. DOI: 10.1186/s13287-022-02858-4.
[13]	OGASAWARA H, INAGAKI A, FATHI I, et al. Preferable transplant site for hepatocyte transplantation in a rat model[J]. Cell Transplant, 2021, 30: 9636897211040012. DOI: 10.1177/09636897211040012.
[14]	YUAN LZ, JIANG J, LIU X, et al. HBV infection-induced liver cirrhosis development in dual-humanised mice with human bone mesenchymal stem cell transplantation[J]. Gut, 2019, 68( 11): 2044- 2056. DOI: 10.1136/gutjnl-2018-316091.
[15]	OHKI A, SAITO S, FUKUCHI K. Magnetic resonance imaging of umbilical cord stem cells labeled with superparamagnetic iron oxide nanoparticles: Effects of labelling and transplantation parameters[J]. Sci Rep, 2020, 10( 1): 13684. DOI: 10.1038/s41598-020-70291-9.
[16]	HERVÁS-SALCEDO R, FERNÁNDEZ-GARCÍA M, HERNANDO-RODRÍGUEZ M, et al. Enhanced anti-inflammatory effects of mesenchymal stromal cells mediated by the transient ectopic expression of CXCR4 and IL10[J]. Stem Cell Res Ther, 2021, 12( 1): 124. DOI: 10.1186/s13287-021-02193-0.
[17]	XU RX, NI BB, WANG L, et al. CCR2-overexpressing mesenchymal stem cells targeting damaged liver enhance recovery of acute liver failure[J]. Stem Cell Res Ther, 2022, 13( 1): 55. DOI: 10.1186/s13287-022-02729-y.
[18]	LI Y, DONG JT, ZHOU Y, et al. Therapeutic effects of CXCL9-overexpressing human umbilical cord mesenchymal stem cells on liver fibrosis in rats[J]. Biochem Biophys Res Commun, 2021, 584: 87- 94. DOI: 10.1016/j.bbrc.2021.10.078.
[19]	WANG Q, LI YW, YUAN H, et al. Hypoxia preconditioning of human amniotic mesenchymal stem cells enhances proliferation and migration and promotes their homing via the HGF/C-MET signaling axis to augment the repair of acute liver failure[J]. Tissue Cell, 2024, 87: 102326. DOI: 10.1016/j.tice.2024.102326.
[20]	ELZAINY A, SADIK A EL, ALTOWAYAN WM. Comparison between the regenerative and therapeutic impacts of bone marrow mesenchymal stem cells and adipose mesenchymal stem cells pre-treated with melatonin on liver fibrosis[J]. Biomolecules, 2024, 14( 3): 297. DOI: 10.3390/biom14030297.
[21]	BAIG MT, GHUFRAN H, MEHMOOD A, et al. Vitamin E pretreated Wharton’s jelly-derived mesenchymal stem cells attenuate CCl₄-induced hepatocyte injury in vitro and liver fibrosis in vivo[J]. Biochem Pharmacol, 2021, 186: 114480. DOI: 10.1016/j.bcp.2021.114480.
[22]	NIE H, AN FM, MEI J, et al. IL-1β pretreatment improves the efficacy of mesenchymal stem cells on acute liver failure by enhancing CXCR4 expression[J]. Stem Cells Int, 2020, 2020: 1498315. DOI: 10.1155/2020/1498315.
[23]	ZHENG J, LI H, HE LY, et al. Preconditioning of umbilical cord-derived mesenchymal stem cells by rapamycin increases cell migration and ameliorates liver ischaemia/reperfusion injury in mice via the CXCR4/CXCL12 axis[J]. Cell Prolif, 2019, 52( 2): e12546. DOI: 10.1111/cpr.12546.
[24]	XU HM, HUANG YZ, ZHANG FS, et al. Ultrasonic microbubbles promote mesenchymal stem cell homing to the fibrotic liver via upregulation of CXCR4 expression[J]. Cell Div, 2024, 19( 1): 7. DOI: 10.1186/s13008-023-00104-8.
[25]	DING F, LIU YT, LI J, et al. TC14012 enhances the anti-fibrosis effects of UC-MSCs on the liver by reducing collagen accumulation and ameliorating inflammation[J]. Stem Cell Res Ther, 2024, 15( 1): 44. DOI: 10.1186/s13287-024-03648-w.
[26]	LE B, CRESSMAN A, MORALES D, et al. First clinical experiences using preconditioning approaches to improve MSC-based therapies[J]. Curr Stem Cell Rep, 2024, 10( 1): 1- 7. DOI: 10.1007/s40778-023-00232-5.
[27]	NASIR GA, MOHSIN S, KHAN M, et al. Mesenchymal stem cells and Interleukin-6 attenuate liver fibrosis in mice[J]. J Transl Med, 2013, 11: 78. DOI: 10.1186/1479-5876-11-78.
[28]	XIANG W, YIN GL, LIU HM, et al. Arctium lappa L. polysaccharides enhanced the therapeutic effects of nasal ectomesenchymal stem cells against liver fibrosis by inhibiting the Wnt/β-catenin pathway[J]. Int J Biol Macromol, 2024, 261( Pt 1): 129670. DOI: 10.1016/j.ijbiomac.2024.129670.
[29]	TAKAYAMA Y, KUSAMORI K, KATSURADA Y, et al. Efficient delivery of mesenchymal stem/stromal cells to injured liver by surface PEGylation[J]. Stem Cell Res Ther, 2023, 14( 1): 216. DOI: 10.1186/s13287-023-03446-w.
[30]	QUE HY, MAI E, HU YT, et al. Multilineage-differentiating stress-enduring cells: A powerful tool for tissue damage repair[J]. Front Cell Dev Biol, 2024, 12: 1380785. DOI: 10.3389/fcell.2024.1380785.
[31]	KATAGIRI H, KUSHIDA Y, NOJIMA M, et al. A distinct subpopulation of bone marrow mesenchymal stem cells, muse cells, directly commit to the replacement of liver components[J]. Am J Transplant, 2016, 16( 2): 468- 483. DOI: 10.1111/ajt.13537.
[32]	ISEKI M, KUSHIDA Y, WAKAO S, et al. Muse cells, nontumorigenic pluripotent-like stem cells, have liver regeneration capacity through specific homing and cell replacement in a mouse model of liver fibrosis[J]. Cell Transplant, 2017, 26( 5): 821- 840. DOI: 10.3727/096368916X693662.
[33]	ISEKI M, MIZUMA M, WAKAO S, et al. The evaluation of the safety and efficacy of intravenously administered allogeneic multilineage-differentiating stress-enduring cells in a swine hepatectomy model[J]. Surg Today, 2021, 51( 4): 634- 650. DOI: 10.1007/s00595-020-02117-0.
[34]	LI H, WEI JH, LI MZ, et al. Biological characteristics of Muse cells derived from MenSCs and their application in acute liver injury and intracerebral hemorrhage diseases[J]. Regen Ther, 2024, 27: 48- 62. DOI: 10.1016/j.reth.2024.03.003.
[35]	CHENG WY, YANG MY, YEH CA, et al. Therapeutic applications of mesenchymal stem cell loaded with gold nanoparticles for regenerative medicine[J]. Pharmaceutics, 2023, 15( 5): 1385. DOI: 10.3390/pharmaceutics15051385.
[36]	HUANG XL, ZHANG F, WANG Y, et al. Design considerations of iron-based nanoclusters for noninvasive tracking of mesenchymal stem cell homing[J]. ACS Nano, 2014, 8( 5): 4403- 4414. DOI: 10.1021/nn4062726.
[37]	VITALE E, ROSSIN D, PERVEEN S, et al. Silica nanoparticle internalization improves chemotactic behaviour of human mesenchymal stem cells acting on the SDF1α/CXCR4 axis[J]. Biomedicines, 2022, 10( 2): 336. DOI: 10.3390/biomedicines10020336.
[38]	ZHANG DX, FU LW, YANG YT, et al. Tetrahedral framework nucleic acids improve the effectiveness of adipose-derived mesenchymal stem cells in the repair of acute liver failure[J]. Mater Today Nano, 2024, 25: 100454. DOI: 10.1016/j.mtnano.2024.100454.
[39]	FOROUTAN T, KASSAEE MZ, SALARI M, et al. Magnetic Fe₃ O₄@graphene oxide improves the therapeutic effects of embryonic stem cells on acute liver damage[J]. Cell Prolif, 2021, 54( 11): e13126. DOI: 10.1111/cpr.13126.
[40]	SHIN MJ, PARK JY, LEE DH, et al. Stem cell mimicking nanoencapsulation for targeting arthritis[J]. Int J Nanomedicine, 2021, 16: 8485- 8507. DOI: 10.2147/IJN.S334298.

Relative Articles

[1]	Xinrui ZHENG, Yannan XU, Danyang WANG, Feifei XING, Mengyao ZONG, Shihao ZHANG, Junyi ZHAN, Wei LIU, Gaofeng CHEN, Jiamei CHEN, Ping LIU, Yongping MU. Therapeutic effect of transplantation of bone marrow mesenchymal stem cells co-cultured with bone marrow M2 macrophages on a rat model of liver cirrhosis[J]. Journal of Clinical Hepatology, 2024, 40(1): 96-103. doi: 10.12449/JCH240117
[2]	Hang DING, Xiaofen LI, Yan XIONG, Yanyan LI, Xiuji CHEN, Xiaolin WANG. Therapeutic effect of mesenchymal stem cells on acute-on-chronic liver failure： A Meta-analysis[J]. Journal of Clinical Hepatology, 2024, 40(8): 1646-1652. doi: 10.12449/JCH240822
[3]	Longlong LUO, Lifei WANG, Ying ZHENG, Bin LI, Lixia LU, Chuyi LI, Xiaohui YU, Jiucong ZHANG. Research advances in mesenchymal stem cells and their exosomes in treatment of autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2023, 39(12): 2920-2925. doi: 10.3969/j.issn.1001-5256.2023.12.025
[4]	Wanwan SHI, Jiandan QIAN, Guiqiang WANG. Clinical research advances in mesenchymal stem cells for the treatment of autoimmune liver diseases[J]. Journal of Clinical Hepatology, 2023, 39(5): 1004-1009. doi: 10.3969/j.issn.1001-5256.2023.05.002
[5]	Zhuoran WANG, Bing ZHU, Limei YU, Shaoli YOU. Role of stem cell-derived exosomes in treatment of liver diseases[J]. Journal of Clinical Hepatology, 2023, 39(3): 699-706. doi: 10.3969/j.issn.1001-5256.2023.03.034
[6]	Yu FENG, Junfeng CHEN, Bingliang LIN. Clinical research advances in mesenchymal stem cells for the treatment of end-stage liver disease[J]. Journal of Clinical Hepatology, 2023, 39(5): 1010-1018. doi: 10.3969/j.issn.1001-5256.2023.05.003
[7]	Lu YANG, Ye XIONG, Jianrong HUANG. Application of human serum albumin in the management of end-stage liver disease[J]. Journal of Clinical Hepatology, 2022, 38(4): 936-941. doi: 10.3969/j.issn.1001-5256.2022.04.040
[8]	Honglin MA, Jing YANG, Qiu JIN, Run LUO, Jiao LENG, Xia WANG. Current status of research on nutritional support in end-stage liver disease[J]. Journal of Clinical Hepatology, 2022, 38(1): 215-219. doi: 10.3969/j.issn.1001-5256.2022.01.038
[9]	Yue LIANG, Yonghong HU, Wei LIU, Yongping MU, Jiamei CHEN, Ping LIU. Research advances in bone marrow mesenchymal stem cells and its exosomes in treatment of end-stage liver disease[J]. Journal of Clinical Hepatology, 2022, 38(11): 2643-2648. doi: 10.3969/j.issn.1001-5256.2022.11.041
[10]	Li DongCeng, Kong Ming, Chen Yu. Association between end-stage liver disease and sarcopenia[J]. Journal of Clinical Hepatology, 2020, 36(3): 693-696. doi: 10.3969/j.issn.1001-5256.2020.03.050
[11]	Chinese Society of Hepatology, Chinese Medical Association, Chinese Society of Gastroenterology, Chinese Medical Association. Clinical guidelines on nutrition in end-stage liver disease[J]. Journal of Clinical Hepatology, 2019, 35(6): 1222-1230. doi: 10.3969/j.issn.1001-5256.2019.06.010
[12]	Zhang YiTong, Xin Lei, Li ZhaoShen. Research advances in mesenchymal stem cells in treatment of end-stage liver disease and their application prospect[J]. Journal of Clinical Hepatology, 2019, 35(9): 2104-2107. doi: 10.3969/j.issn.1001-5256.2019.09.049
[13]	Zhu Bin, Zou CongCong, Zheng Xin. Malnutrition assessment and nutrition support therapy for end-stage liver disease[J]. Journal of Clinical Hepatology, 2017, 33(9): 1699-1706. doi: 10.3969/j.issn.1001-5256.2017.09.014
[14]	Wang DongDong, Chen Gang, Hu ZongQiang, Li Li. Research advances in mesenchymal stem cells from various sources in treatment of liver fibrosis[J]. Journal of Clinical Hepatology, 2016, 32(3): 597-600. doi: 10.3969/j.issn.1001-5256.2016.03.044
[15]	Zhang LiTing. Advances in basic research on mesenchymal stem cells and its clinical application in liver cirrhosis[J]. Journal of Clinical Hepatology, 2016, 32(6): 1196-1198. doi: 10.3969/j.issn.1001-5256.2016.06.042
[16]	Ma LinJie, Chen Gang, Hu ZongQiang, Liu Hong, Wang DongDong, Fang He, Jin Xiong. Mechanism of treatment of acute-on-chronic liver failure with mesenchyaml stem cells[J]. Journal of Clinical Hepatology, 2015, 31(9): 1505-1508. doi: 10.3969/j.issn.1001-5256.2015.09.037
[17]	Lu: SuLi, Ma Yong, Ding TiLong. Bone marrow mesenchymal stem cells as therapy for hepatic fibrosis[J]. Journal of Clinical Hepatology, 2012, 28(11): 819-823.
[18]	Xie Chan, Peng Liang, Ye YiNong, Zhang GengLin, Xie ShiBin, Gao ZhiLiang. Bone marrow mesenchymal stem cells regulated hepatic stellate cells activation through LPS-TLR4 pathway[J]. Journal of Clinical Hepatology, 2011, 27(5): 521-524.
[19]	Song XiaoJing, Song HongLi, Zheng WeiPing, Wang ZhengLu, Gong HuiBin, Shen ZhongYang. The protective effects of bone-marrow-derived mesenchymal stem cells on hepatic regeneration and repair of rat liver graft after reduced-size liver transplantation[J]. Journal of Clinical Hepatology, 2011, 27(2): 184-188.
[20]	Xiong YunChuan, Gao Hong, Li Min. The application of bone marrow mesenchymal stem cells transplantation in liver regeneration[J]. Journal of Clinical Hepatology, 2011, 27(9): 995-998.

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Tables(3)

Get Citation

PDF

XML

Article Metrics

Article views (46) PDF downloads(8)

Influencing factors for the homing ability of mesenchymal stem cells in end-stage liver disease and optimization measures

DOI: 10.12449/JCH250326

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Influencing factors for the homing ability of mesenchymal stem cells in end-stage liver disease and optimization measures

DOI: 10.12449/JCH250326

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content